Bicara CFO exercises options and sells 12,500 shares
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options for 12,500 shares of common stock at an exercise price of $3.7898 per share and on the same day sold 12,500 shares at a weighted average price of $27.9673 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options for 12,500 shares of common stock at an exercise price of $3.7898 per share and on the same day sold 12,500 shares at a weighted average price of $27.9673 per share. The option exercise reduced the reported option position to 26,336 stock options following the transaction, with the options expiring on April 5, 2033 and vesting in sixteen equal quarterly installments following April 5, 2023. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 12,500 shares ($302K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Hyep Ivan
Role
Chief Financial Officer
Sold
12,500 shs ($350K)
Approx. gross sale proceeds
$350K
Approx. exercise cost
$47K
Approx. pre-tax spread
$302K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 12,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 12,500 | $3.7898 | $47K |
| Sale | Common Stock F1, F2 | 12,500 | $27.9673 | $350K |
Holdings After Transaction:
Stock Option (Right to Buy) — 26,336 contracts (Direct);
Common Stock — 129,855 shares (Direct)
Footnotes (3)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.675 to $28.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options exercised: 12,500 shares
Option exercise price: $3.7898 per share
Shares sold: 12,500 shares
+5 more
8 metrics
Options exercised
12,500 shares
Stock options exercised into common stock on August 10, 2026
Option exercise price
$3.7898 per share
Exercise price for 12,500 stock options converted to common stock
Shares sold
12,500 shares
Common shares sold on August 10, 2026 following option exercise
Weighted average sale price
$27.9673 per share
Weighted average; individual trades ranged from $27.675 to $28.185
Remaining options
26,336 options
Total stock options reported following the option exercise
Option expiration date
April 5, 2033
Expiration date of the stock option position involved in this exercise
10b5-1 plan adoption date
March 31, 2026
Date the Rule 10b5-1 trading plan governing these trades was adopted
Vesting schedule
16 quarterly installments
Options vest in sixteen equal quarterly installments after April 5, 2023
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vesting financial
"shares underlying this option vest in sixteen equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BCAX CFO Hyep Ivan report in this Form 4?
Hyep Ivan exercised options for 12,500 shares of Bicara Therapeutics common stock at $3.7898 per share and sold 12,500 shares at a weighted average price of $27.9673 per share, all dated August 10, 2026.
How many Bicara Therapeutics options does BCAX CFO Hyep Ivan hold after this transaction?
After exercising 12,500 options, Hyep Ivan reported holding 26,336 stock options following the transaction. These options relate to Bicara Therapeutics common stock and are scheduled to expire on April 5, 2033.
Were BCAX CFO Hyep Ivan’s Bicara Therapeutics trades under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026, indicating they followed a pre-arranged trading schedule.
How do Hyep Ivan’s Bicara Therapeutics options vest according to this Form 4?
The Form 4 notes that the shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to Hyep Ivan’s continued service on each applicable vesting date.
What is the significance of the $3.7898 exercise price for BCAX options?
The $3.7898 figure is the per-share exercise price for the 12,500 stock options converted into Bicara Therapeutics common stock. It reflects the cost per share paid upon exercising the derivative security on August 10, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
